NO20071617L - Indozolonderivater som 11B-HSD1-inhibitorer - Google Patents
Indozolonderivater som 11B-HSD1-inhibitorerInfo
- Publication number
- NO20071617L NO20071617L NO20071617A NO20071617A NO20071617L NO 20071617 L NO20071617 L NO 20071617L NO 20071617 A NO20071617 A NO 20071617A NO 20071617 A NO20071617 A NO 20071617A NO 20071617 L NO20071617 L NO 20071617L
- Authority
- NO
- Norway
- Prior art keywords
- indozolone
- derivatives
- hsd1 inhibitors
- compounds
- formula
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04104753 | 2004-09-29 | ||
| PCT/EP2005/010175 WO2006034804A1 (en) | 2004-09-29 | 2005-09-21 | Indozolone derivatives as 11b-hsd1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20071617L true NO20071617L (no) | 2007-04-20 |
Family
ID=35447579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20071617A NO20071617L (no) | 2004-09-29 | 2007-03-27 | Indozolonderivater som 11B-HSD1-inhibitorer |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7528158B2 (de) |
| EP (1) | EP1797042B1 (de) |
| JP (1) | JP4682207B2 (de) |
| KR (1) | KR100856164B1 (de) |
| CN (1) | CN101027286B (de) |
| AR (1) | AR050952A1 (de) |
| AT (1) | ATE420076T1 (de) |
| AU (1) | AU2005289107B2 (de) |
| BR (1) | BRPI0515931A (de) |
| CA (1) | CA2581865C (de) |
| DE (1) | DE602005012292D1 (de) |
| DK (1) | DK1797042T3 (de) |
| ES (1) | ES2317305T3 (de) |
| HR (1) | HRP20090151T3 (de) |
| IL (1) | IL182212A (de) |
| MX (1) | MX2007003546A (de) |
| MY (1) | MY140841A (de) |
| NO (1) | NO20071617L (de) |
| NZ (1) | NZ553849A (de) |
| PL (1) | PL1797042T3 (de) |
| PT (1) | PT1797042E (de) |
| RU (1) | RU2392272C2 (de) |
| SG (1) | SG148178A1 (de) |
| SI (1) | SI1797042T1 (de) |
| TW (1) | TWI309646B (de) |
| WO (1) | WO2006034804A1 (de) |
| ZA (1) | ZA200702394B (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7579360B2 (en) | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| US8318941B2 (en) | 2006-07-06 | 2012-11-27 | Bristol-Myers Squibb Company | Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
| CL2008001839A1 (es) | 2007-06-21 | 2009-01-16 | Incyte Holdings Corp | Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades. |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US20090076783A1 (en) * | 2007-09-13 | 2009-03-19 | Tyco Healthcare Retail Services Ag | Digitally optimized fastener assembly and method of making the same |
| US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| AU2009220458A1 (en) * | 2008-03-06 | 2009-09-11 | Merck Sharp & Dohme Corp. | Hexahydrocyclopentyl[f]findazole sulfonamides and derivates thereof as selective glucocorticoid receptor modulators |
| US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| ES2443016T3 (es) | 2009-08-26 | 2014-02-17 | Sanofi | Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (de) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren |
| EP3235813A1 (de) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo-derivate |
| KR101796781B1 (ko) | 2016-05-20 | 2017-11-13 | 한국화학연구원 | 신규한 인다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 질환의 예방 또는 치료용 약학적 조성물 |
| MX2021008364A (es) | 2019-01-11 | 2021-08-05 | Gruenenthal Gmbh | Amidas de pirrolidina iii sustituidas. |
| WO2021021951A1 (en) | 2019-07-29 | 2021-02-04 | Vanderbilt University | Wdr5-myc inhibitors |
| CN116829524A (zh) * | 2021-01-06 | 2023-09-29 | 中外制药株式会社 | 酸性官能团的烷基化方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL84944A (en) | 1987-01-19 | 1992-02-16 | Ici Plc | Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation |
| GB9805520D0 (en) | 1998-03-17 | 1998-05-13 | Zeneca Ltd | Chemical compounds |
| SE0001899D0 (sv) * | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
| FR2836914B1 (fr) * | 2002-03-11 | 2008-03-14 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| EP1507756B1 (de) | 2002-05-24 | 2015-07-22 | Millennium Pharmaceuticals, Inc. | Ccr9-inhibitoren und verfahren zu deren verwendung |
| AU2004305321A1 (en) * | 2003-12-19 | 2005-07-07 | Pfizer Inc. | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
-
2005
- 2005-09-21 PT PT05791184T patent/PT1797042E/pt unknown
- 2005-09-21 CN CN2005800322682A patent/CN101027286B/zh not_active Expired - Fee Related
- 2005-09-21 AU AU2005289107A patent/AU2005289107B2/en not_active Ceased
- 2005-09-21 ES ES05791184T patent/ES2317305T3/es not_active Expired - Lifetime
- 2005-09-21 RU RU2007116033/04A patent/RU2392272C2/ru not_active IP Right Cessation
- 2005-09-21 AT AT05791184T patent/ATE420076T1/de active
- 2005-09-21 SG SG200808470-9A patent/SG148178A1/en unknown
- 2005-09-21 CA CA2581865A patent/CA2581865C/en not_active Expired - Fee Related
- 2005-09-21 SI SI200530605T patent/SI1797042T1/sl unknown
- 2005-09-21 WO PCT/EP2005/010175 patent/WO2006034804A1/en not_active Ceased
- 2005-09-21 NZ NZ553849A patent/NZ553849A/en not_active IP Right Cessation
- 2005-09-21 PL PL05791184T patent/PL1797042T3/pl unknown
- 2005-09-21 DE DE602005012292T patent/DE602005012292D1/de not_active Expired - Lifetime
- 2005-09-21 HR HR20090151T patent/HRP20090151T3/xx unknown
- 2005-09-21 BR BRPI0515931-8A patent/BRPI0515931A/pt not_active IP Right Cessation
- 2005-09-21 KR KR1020077007018A patent/KR100856164B1/ko not_active Expired - Fee Related
- 2005-09-21 EP EP05791184A patent/EP1797042B1/de not_active Expired - Lifetime
- 2005-09-21 DK DK05791184T patent/DK1797042T3/da active
- 2005-09-21 JP JP2007533911A patent/JP4682207B2/ja not_active Expired - Fee Related
- 2005-09-21 MX MX2007003546A patent/MX2007003546A/es active IP Right Grant
- 2005-09-26 US US11/235,375 patent/US7528158B2/en not_active Expired - Fee Related
- 2005-09-26 AR ARP050104014A patent/AR050952A1/es unknown
- 2005-09-26 TW TW094133289A patent/TWI309646B/zh not_active IP Right Cessation
- 2005-09-27 MY MYPI20054555A patent/MY140841A/en unknown
-
2007
- 2007-03-22 ZA ZA200702394A patent/ZA200702394B/xx unknown
- 2007-03-26 IL IL182212A patent/IL182212A/en not_active IP Right Cessation
- 2007-03-27 NO NO20071617A patent/NO20071617L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20071617L (no) | Indozolonderivater som 11B-HSD1-inhibitorer | |
| NO20091548L (no) | Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes | |
| NO20071658L (no) | Alkil-pyridiner som 11-beta-inhibitorer for diabetes | |
| NO20070445L (no) | Pyrimidinderivater. | |
| NO20080554L (no) | Pyrazolonderivater | |
| NO20070458L (no) | Aryl-pyridinderivater som 11-Beta-HSD1 inhibitorer | |
| NO20084418L (no) | Azolopyridin-3-on derivater som inhibitorer av endoteliallipase | |
| NO20082159L (no) | Triazolopyridinderivater som inhibitorer av lipaser og fosfolipaser | |
| NO20082388L (no) | Heteroaryl substituerte piperidinderivater som L-CPT1 inhibitorer | |
| NO20076648L (no) | Novel thiophene derivatives | |
| NO20054852L (no) | GFAT inhibitorer | |
| NO20081942L (no) | Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser | |
| NO20081315L (no) | Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser | |
| NO20092723L (no) | Indazolylester og amidderivater for behandling av gluccocorticoid reseptormedierte sykdommer | |
| NO20084129L (no) | Pyridin(3,4-B)Pyrazinoner | |
| NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
| NO20071593L (no) | Pyrimidinderivater | |
| NO20091409L (no) | Pyridin-3-yl-derivater som immunmodulerende midler | |
| NO20083514L (no) | Heterobicykliske sulfonamidderivater for behandling av diabetes | |
| WO2005051906A3 (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
| NO20071137L (no) | Nye piperidinderivater for behandling av depresjon | |
| NO20063925L (no) | Indazolderivater som inhibitorer av hormonsensitiv lipase | |
| NO20091553L (no) | Fenylderivater og deres anvendelse som immunmodulatorer | |
| NO20055421L (no) | Kinolinderivater som fosfodiestrase-inhibitorer | |
| NO20063231L (no) | Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |